Xilio Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 23, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 23, 2026
XLO$9.00+4.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(In thousands, except share and per share data)
| December 31, · December 31, | ||||
|---|---|---|---|---|
| 2025 · 2024 | ||||
| ASSETS | ||||
| Current assets | ||||
| Cash and cash equivalents | $ | 137,531 | $ | 55,291 |
| Collaboration and license agreement receivable | 5,000 | — | ||
| Prepaid expenses and other current assets | 2,496 | 4,943 | ||
| Total current assets | 145,027 | 60,234 | ||
| Restricted cash | 1,807 | 1,782 | ||
| Property and equipment, net | 3,892 | 4,472 | ||
| Operating lease right-of-use asset | 3,959 | 4,587 | ||
| Total assets | $ | 154,685 | $ | 71,075 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||
| Current liabilities | ||||
| Accounts payable | $ | 3,168 | $ | 2,574 |
| Accrued expenses | 11,739 | 9,981 | ||
| Deferred revenue, current portion | 40,023 | 13,518 | ||
| Operating lease liability, current portion | 1,343 | 1,188 | ||
| Total current liabilities | 56,273 | 27,261 | ||
| Deferred revenue, net of current portion | 20,635 | 19,262 | ||
| Operating lease liability, net of current portion | 5,611 | 6,954 | ||
| Common stock warrant liabilities | 29,560 | — | ||
| Liabilities to issue common stock | 7,333 | — | ||
| Total liabilities | 119,412 | 53,477 | ||
| Commitments and contingencies (Note 8) | ||||
| Stockholders’ equity | ||||
| Preferred stock, $0.0001 par value; 5,000,000 shares authorized, no shares issued or outstanding | — | — | ||
| Common stock, $0.0001 par value; 600,000,000 shares authorized at December 31, 2025 and 200,000,000 shares authorized at December 31, 2024; 4,530,641 shares issued and outstanding at December 31, 2025; 3,268,299 shares issued and outstanding at December 31, 2024 | — | — | ||
| Additional paid-in capital | 454,062 | 401,351 | ||
| Accumulated deficit | (418,789) | (383,753) | ||
| Total stockholders’ equity | 35,273 | 17,598 | ||
| Total liabilities and stockholders’ equity | $ | 154,685 | $ | 71,075 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.